The Prognostic and Predictive Significance of PARP-1 in Locally Advanced Breast Cancer of Egyptian Patients Receiving Neoadjuvant Chemotherapy
- 1 September 2015
- journal article
- research article
- Published by Wolters Kluwer Health in Applied Immunohistochemistry & Molecular Morphology
- Vol. 23 (8) , 571-579
Abstract
Purpose: PARP-1 is a chromatin-associated enzyme that has a role in DNA repair and cell death. PARP-1 inhibitors are suggested therapy specifically for BRCA deficient breast carcinoma; however, their efficacy in sporadic breast cancer is under investigations. This study aimed to evaluate the PARP-1 in locally advanced breast cancer (LABC) cases to determine its predictive significance for outcome and response to neoadjuvant chemotherapy (NCT). Materials and Methods: This retrospective study was conducted on 84 LABC cases. Immunohistochemical expression of nuclear PARP-1 (nPARP-1) and cytoplasmic PARP-1 (cPARP-1) was evaluated in pretreatment needle core biopsies (NCBs). Results were correlated with clinicopathologic features, overall survival (OS), disease-free survival (DFS), and response to NCT in postoperative specimens. Results: High nPARP-1expression was observed in 64/84 (76%) of cases and was significantly associated with a lower lymph node stage (P=0.04). High cPARP-1 was observed in 40/84 (48%) of cases and it was significantly associated with lower lymph node stage (P=0.022) and lower tumor grade (P=0.050). High nPARP-1 expression was significantly associated with high cPARP-1 expression (P=0.005). Low cPARP-1 expression was associated with no response to chemotherapy in tumor site (P=0.021). According to the univariate survival analysis, high nPARP-1 and high cPARP-1 were significantly associated to longer OS (P=0.017 and P=0.019, respectively). High nPARP-1 but not cPARP-1 showed trend toward improved OS in multivariate Cox-regression analysis (P=0.053). Conclusion: PARP-1 immunohistochemical expression is a marker of good prognosis and is predictive of response to NCT in LABC.Keywords
This publication has 44 references indexed in Scilit:
- Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor TypesGenes & Cancer, 2010
- A Nuclear Poly(ADP-Ribose)-Dependent Signalosome Confers DNA Damage-Induced IκB Kinase ActivationMolecular Cell, 2009
- DNA polymerase β and PARP activities in base excision repair in living cellsDNA Repair, 2009
- PARP-1 is involved in autophagy induced by DNA damageAutophagy, 2009
- A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break RepairJournal of Clinical Oncology, 2008
- Anti‐inflammatory effects of PJ34, a poly(ADP‐ribose) polymerase inhibitor, in transient focal cerebral ischemia in miceBritish Journal of Pharmacology, 2006
- The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) InhibitorsInternational Journal of Biological Sciences, 2006
- Poly(ADP-ribose) is required for spindle assembly and structureNature, 2004
- NAD+-Dependent Modulation of Chromatin Structure and Transcription by Nucleosome Binding Properties of PARP-1Cell, 2004
- (ADP-ribose)n participates in DNA excision repairNature, 1980